Education & Professional Experience

Pearl has studied at University of Southern California in Clinical Neuroscience between 1998 and 2003, then at University of Southern California in Clinical Neuroscience between 1998 and 2000, then at University of Southern California in Psychology and Pre-medical track between 1991 and 1996.

Pearl worked for NKMax America, Inc. as Vice President, Clinical Development and Clinical Operations - NK Cell Therapy between Oct 2018 and Nov 2019, for ARMO BioSciences (wholly-owned subsidiary of Eli Lilly and Company) as Senior Director, Clinical Development - Immuno-Oncology between Mar 2018 and Oct 2018, for Puma Biotechnology, Inc. as Clinical Scientist, Clinical Development - Oncology between Mar 2016 and Mar 2018, for Celldex Therapeutics as Director, Medical Affairs - Immuno-Oncology between Nov 2015 and Mar 2016, for Amgen as Senior Regional Medical Liaison - Hematology, Immuno-Oncology between Jan 2012 and Nov 2015, for Onyx Pharmaceuticals, Inc. (wholly-owned subsidiary of Amgen, Inc.) as Clinical Scientist - Hematology, Oncology between Nov 2010 and Jan 2012, for Cephalon as Senior Medical Science Liaison - Hematology, Oncology between Oct 2006 and Nov 2010, for Eli Lilly and Company as Senior Sales Specialist - Oncology, Osteoporosis, Neuroscience between May 2003 and Oct 2006.

 Skills & Competences

Pearl has the following skills : Biopharmaceuticals, Biotechnology, Hematology, Therapeutic Areas, Drug Development, Medical Affairs, Oncology, Clinical Development, Internal Medicine, Hospitals, Molecular Biology, Pharmacy, Cancer, Pharmaceutical Industry, Medical Education, Osteoporosis, Clinical Research, Medicine, Clinical Trials, Pharmacology.